|
PMID 35940589
|
Two Years into the COVID-19 Pandemic: Lessons Learned |
Da Silva |
2022 |
|
-
|
The Animal Origin of Major Human Infectious Diseases: What Can Past Epidemics Teach Us About Preventing the Next Pandemic? Zoonoses. 2022;2(1) |
Dharmarajan |
2022 |
|
PMID 32015507
|
A pneumonia outbreak associated with a new coronavirus of probable bat origin |
Zhou |
2020 |
|
PMID 30531947
|
Origin and evolution of pathogenic coronaviruses |
Cui |
2019 |
|
PMID 15035025
|
SARS—beginning to understand a new virus |
Stadler |
2003 |
|
PMID 22816037
|
Mechanisms of Coronavirus Cell Entry Mediated by the Viral Spike Protein |
Belouzard |
2012 |
|
PMID 34611326
|
Mechanisms of SARS-CoV-2 entry into cells |
Jackson |
2022 |
|
PMID 32142651
|
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor |
Hoffmann |
2020 |
|
PMID 32275855
In OmniVira
|
Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. |
Wang |
2020 |
|
PMID 34504054
|
The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice |
Sun |
2021 |
|
PMID 33773111
|
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials |
Yang |
2021 |
|
PMID 34197281
|
Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial |
Zhang |
2021 |
|
PMID 33045718
|
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies |
Barnes |
2020 |
|
PMID 34001847
|
Rapid isolation and immune profiling of SARS-CoV-2 specific memory B cell in convalescent COVID-19 patients via LIBRA-seq |
He |
2021 |
|
PMID 35016195
|
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift |
Cameroni |
2022 |
|
PMID 34149735
|
Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern |
Deshpande |
2021 |
|
PMID 33724631
|
Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines |
Focosi |
2021 |
|
PMID 34234131
|
Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies |
Greaney |
2021 |
|
PMID 32942285
|
Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion |
Benton |
2020 |
|
PMID 32155444
In OmniVira
|
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. |
Walls |
2020 |
|
PMID 33493182
|
Furin cleavage of SARS-CoV-2 Spike promotes but is not essential for infection and cell-cell fusion |
Papa |
2021 |
|
PMID 32272173
|
Coronavirus membrane fusion mechanism offers a potential target for antiviral development |
Tang |
2020 |
|
PMID 34930824
|
SARS-CoV-2 spike engagement of ACE2 primes S2’ site cleavage and fusion initiation |
Yu |
2022 |
|
PMID 30626688
|
TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection |
Iwata-Yoshikawa |
2019 |
|
PMID 33774649
|
Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development |
Zhao |
2021 |
|
PMID 32231345
|
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion |
Xia |
2020 |
|
PMID 34274319
|
Membranotropic and biological activities of the membrane fusion peptides from SARS-CoV spike glycoprotein: The importance of the complete internal fusion peptide domain |
Basso |
2021 |
|
PMID 34929193
|
Negatively charged residues in the membrane ordering activity of SARS-CoV-1 and -2 fusion peptides |
Lai |
2022 |
|
PMID 35157798
|
Strikingly Different Roles of SARS-CoV-2 Fusion Peptides Uncovered by Neutron Scattering |
Santamaria |
2022 |
|
PMID 32057769
|
The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade |
Coutard |
2020 |
|
PMID 32009228
|
Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission |
Xu |
2020 |
|
PMID 32376634
|
Cell entry mechanisms of SARS-CoV-2 |
Shang |
2020 |
|
PMID 32075877
In OmniVira
|
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. |
Wrapp |
2020 |
|
PMID 19439480
|
Characterization of a highly conserved domain within the severe acute respiratory syndrome coronavirus spike protein S2 domain with characteristics of a viral fusion peptide |
Madu |
2009 |
|
PMID 27030273
|
Identification of the Fusion Peptide-Containing Region in Betacoronavirus Spike Glycoproteins |
Ou |
2016 |
|
PMID 35266815
|
Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion. mBio. 2022;13(2):e0009922 |
Ren |
2022 |
|
PMID 33051876
|
Syncytia formation by SARS-CoV-2-infected cells |
Buchrieser |
2020 |
|
PMID 34606831
|
The Mechanism and Consequences of SARS-CoV-2 Spike-Mediated Fusion and Syncytia Formation |
Rajah |
2022 |
|
PMID 34159616
|
TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect host cells |
Koch |
2021 |
|
PMID 33391636
|
Extracellular vesicles containing ACE2 efficiently prevent infection by SARS-CoV-2 Spike protein-containing virus |
Cocozza |
2020 |
|
PMID 33999369
|
A Convenient and Biosafe Replicon with Accessory Genes of SARS-CoV-2 and Its Potential Application in Antiviral Drug Discovery |
Jin |
2021 |
|
PMID 34851142
|
Development of a Single-Cycle Infectious SARS-CoV-2 Virus Replicon Particle System for Use in Biosafety Level 2 Laboratories |
Malicoat |
2022 |
|
PMID 34648371
|
Replication and single-cycle delivery of SARS-CoV-2 replicons |
Ricardo-Lax |
2021 |
|
PMID 34611365
|
Expression and characterization of SARS-CoV-2 spike proteins |
Schaub |
2021 |
|
PMID 35994646
|
SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern |
Lu |
2022 |
|
PMID 32703906
|
Structure-based design of prefusion-stabilized SARS-CoV-2 spikes |
Hsieh |
2020 |
|
PMID 28807998
|
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen |
Pallesen |
2017 |
|
PMID 30356097
|
Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis |
Kirchdoerfer |
2018 |
|
PMID 17620608
In OmniVira
|
Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. |
Zhu |
2007 |
|
PMID 27578435
|
Structure, Function, and Evolution of Coronavirus Spike Proteins |
Li |
2016 |
|
PMID 35668062
|
Novel cleavage sites identified in SARS-CoV-2 spike protein reveal mechanism for cathepsin L-facilitated viral infection and treatment strategies |
Zhao |
2022 |
|
PMID 33820827
|
Crystal structure of inhibitor-bound human MSPL that can activate high pathogenic avian influenza |
Ohno |
2021 |
|
PMID 35585971
|
Furin and TMPRSS2 Resistant Spike Induces Robust Humoral and Cellular Immunity Against SARS-CoV-2 Lethal Infection |
Lin |
2022 |
|
PMID 35343766
|
Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity |
Essalmani |
2022 |
|
PMID 33037310
|
The sequence at Spike S1/S2 site enables cleavage by furin and phospho-regulation in SARS-CoV2 but not in SARS-CoV1 or MERS-CoV |
Örd |
2020 |
|
PMID 32225175
In OmniVira
|
Structural basis of receptor recognition by SARS-CoV-2. |
Shang |
2020 |
|
PMID 33907312
|
The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets |
Peacock |
2021 |
|
PMID 33043289
|
Structures and dynamics of the novel S1/S2 protease cleavage site loop of the SARS-CoV-2 spike glycoprotein |
Lemmin |
2020 |
|
PMID 36580912
|
SARS-CoV-2 replication in airway epithelia requires motile cilia and microvillar reprogramming |
Wu |
2023 |
|
PMID 33465165
|
Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2 |
Ou |
2021 |
|
PMID 31406574
|
Furin-mediated protein processing in infectious diseases and cancer |
Braun |
2019 |
|
PMID 34856891
|
A second functional furin site in the SARS-CoV-2 spike protein |
Zhang |
2022 |
|
PMID 33654293
|
Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics |
Muus |
2021 |
|
PMID 16081529
|
Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry |
Simmons |
2005 |
|
PMID 16339146
|
SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells |
Huang |
2006 |
|
PMID 32376627
|
Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity |
Zhu |
2020 |
|
PMID 32798769
|
From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses |
Kirtipal |
2020 |
|
PMID 32697968
|
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus |
Korber |
2020 |
|
PMID 33863729
|
The SARS-CoV-2 Spike variant D614G favors an open conformational state |
Mansbach |
2021 |
|
PMID 34311586
|
D614G Substitution of SARS-CoV-2 Spike Protein Increases Syncytium Formation and Virus Titer via Enhanced Furin-Mediated Spike Cleavage. mBio. 2021;12(4):e0058721 |
Cheng |
2021 |
|
PMID 32422645
|
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody |
Pinto |
2020 |
|
PMID 31462573
In OmniVira
|
Avian Flavivirus Infection of Monocytes/Macrophages by Extensive Subversion of Host Antiviral Innate Immune Responses. |
Ma |
2019 |
|
PMID 29625056
|
Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies |
Chen |
2018 |
|
PMID 35039785
|
A comprehensive evolutionary and epidemiological characterization of insertion and deletion mutations in SARS-CoV-2 genomes |
Liu |
2021 |